Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL3922894 | 1.00 | — | — | |
| Cysteine SCHEMBL3697868 | 0.97 | — | — | |
| Cysteine SCHEMBL11873934 | 0.94 | — | — | |
| Cysteine SCHEMBL27709352 | 0.94 | — | — | |
| Cysteine SCHEMBL27709351 | 0.94 | — | — | |
| Cysteine SCHEMBL28854295 | 0.94 | PTGS1 (0.89) | — | |
| Cysteine SCHEMBL7898895 | 0.94 | PTGS1 (1.00) | — | |
| Cysteine SCHEMBL95110 | 0.94 | — | — | |
| Cysteine SCHEMBL339562 | 0.94 | PTGS1 (1.00) | — | |
| Cysteine SCHEMBL21110883 | 0.94 | PTGS1 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250195439-A1 | METHOD FOR TREATING LOCAL LESION DISEASE | CHENGDU KUACHANGAOPU MEDICAL TECHNOLOGY CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-3845247-B1 | USE OF AMINO ACID BASED NUTRIENTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHENGDU KUACHANGAOPU MEDICAL TECH CO LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-115398236-B | Method for the electrophoretic deglycosylation of glycosylated proteins | 瑞泽恩制药公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11968998-B2 | L-cysteine-treated proteins with altered functionalities and preparations thereof | MGPI PROCESSING, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-4354145-A2 | DEGLYCOSYLATION METHODS FOR ELECTROPHORESIS OF GLYCOSYLATED PROTEINS | Regeneron Pharmaceuticals, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117887613-A | Bifidobacterium longum subspecies infantis capable of relieving autism spectrum disorder and application thereof | 深圳未知君生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117871866-A | System and method for characterizing protein dimerization | 瑞泽恩制药公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4348234-A1 | MICROPCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS | Regeneron Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4085253-B1 | DEGLYCOSYLATION METHODS FOR ELECTROPHORESIS OF GLYCOSYLATED PROTEINS | REGENERON PHARMA (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-2292585-A1 | Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound | APTUIT (KANSAS CITY), LLC (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20090281195-A1 | NOVEL COCRYSTALLIZATION | S.S.C.I., INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7452555-B2 | Cocrystallization | S.S.C.I., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287194-A1 | Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound | S.S.C.I., INC | 2007-12-13 | — | — | US | disclosed |
| US-20070088508-A1 | Cocrystallization methods | APTUIT (WEST LAFAYETTE), LLC | 2007-04-19 | — | — | US | disclosed |
| EP-1265612-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | LILLY CO ELI (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6686365-B2 | Pharmaceutical composition | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20030212083-A1 | PHARMACEUTICAL COMPOSITION | LILLY FORSCHUNG GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| EP-1265612-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001056575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |